Back to top

Image: Bigstock

Weyerhaeuser (WY) Tops Q2 Earnings & Revenue Estimates

Read MoreHide Full Article

Weyerhaeuser Company (WY - Free Report) is one of the leading U.S. forest product companies, offering logs, hardwood lumber, timber, poles and plywood, as well as minerals, oil, gas, seeds and seedlings to a diversified client base in the U.S., Canada, Japan, Europe and other regions.

However, the company faces risks from high debt levels, industry competition, shortages of skilled labor and lack of suitable lot and mortgage availability.

Weyerhaeuser’s financial performance in the three of last four quarters were better-than-expected, while was below expectation in one. Average earnings surprise was a positive 2.76%.

Weyerhaeuser Company Price and EPS Surprise

 

Weyerhaeuser Company Price and EPS Surprise | Weyerhaeuser Company Quote

Currently, Weyerhaeuser has a Zacks Rank #2 (Buy), but that could definitely change after the release of its upcoming earnings report. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Weyerhaeuser reported earnings, before special items, of 44 cents per share in second-quarter 2018. The bottom line result came in above the Zacks Consensus Estimate of 41 cents per share.

Revenue: Weyerhaeuser generated revenues of $2.1 billion in the quarter. The result was above the Zacks Consensus Estimate of $1.99 billion.

Key Stats to Note: The company anticipates sequentially higher earnings and adjusted EBITDA for its Real Estate, Energy & Natural Resources segment in the third quarter 2018, while predicts lower earnings and adjusted EBITDA for the Wood Products segment.

Stock Price: Weyerhaeuser shares were up 1.7% in the pre-market trading session at the time of writing.

Check back our full write up on this WY earnings report later!

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>
 


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Weyerhaeuser Company (WY) - free report >>

Published in